Deep brain stimulation (DBS) has been used for more than three decades to treat motor symptoms of Parkinson’s disease. Today, more than 200,000 patients worldwide have been implanted with these systems, which continuously deliver electrical stimulation to specific deep-brain regions to reduce rigidity and tremor. Yet despite its clinical success, conventional deep brain stimulation remains limited in its ability to address one of the disease’s most disabling symptoms: walking impairments.

Monash University researchers have found in laboratory experiments that a drug that delivers copper to the brain significantly reduces toxic Alzheimer’s proteins and improves long-term spatial memory.

There are few treatment options available for people with disorders of the esophagus. Delivering drugs directly to this part of the body is difficult, so patients are usually treated with systemic drugs, which can have unwanted side effects.

Following infection, the Ebola virus can survive unnoticed in the human body for months or even years, hiding in areas with little immune surveillance like the central nervous system.